AGN-242428 in the Treatment of Plaque Psoriasis
Phase 2
Terminated
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: AGN-242428Drug: Placebo
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Vitae Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03339999
- Locations
- 🇺🇸
Total Skin and Beauty Dermatology Center, PC, Birmingham, Alabama, United States
🇺🇸Johnson Dermatology, Fort Smith, Arkansas, United States
🇺🇸First OC Dermatology, Fountain Valley, California, United States
An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis
Phase 1
Completed
- Conditions
- Dermatitis, Atopic
- Interventions
- Drug: VTP-38543Other: Vehicle without Transcutol®POther: Vehicle with Transcutol®P
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Vitae Pharmaceuticals, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT02655679
- Locations
- 🇨🇦
Kirk Barber Research, Calgary, Alberta, Canada
🇨🇦Stratica Medical Inc, Edmonton, Alberta, Canada
🇺🇸Skin Specialty Dermatology, New York, New York, United States
Direct Renin Inhibition and the Kidney
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2016-02-29
- Lead Sponsor
- Vitae Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01217736
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath